The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Subscribe To Our Newsletter & Stay Updated
